Stereotactic Body Radiotherapy: is less fractionation more effective in adrenal and renal malignant lesions? - Summary - MDSpire

Stereotactic Body Radiotherapy: is less fractionation more effective in adrenal and renal malignant lesions?

  • By

  • Daniel Rivas

  • Alejandro de la Torre-Luque

  • Elena Moreno-Olmedo

  • Paloma Moreno

  • Vladimir Suárez

  • Ana Serradilla

  • Gregorio Arregui

  • David Álvarez

  • Morena Sallabanda

  • Antonio Lazo

  • María Isabel Núñez

  • Escarlata López

  • July 24, 2024

  • 0 min

Share

Objective:

To analyze how tumor-, patient-, and treatment-related factors influence the outcomes and side effects of SBRT, specifically focusing on local control rates and adverse events, and assess its benefits as an alternative to surgery.

Key Findings:
  • SBRT is a promising non-invasive treatment option for RCC and AM, potentially improving local control rates.
  • Higher Biological Equivalent Dose (BED) may overcome radioresistance in RCC, suggesting a need for tailored dosing strategies.
  • SBRT has shown potential for local control and treatment response in patients with inoperable lesions, indicating its role in expanding treatment options.
Interpretation:

SBRT may provide an effective alternative to surgery for patients with RCC and AM, particularly in those who are inoperable or refuse surgery.

Limitations:
  • Retrospective design may introduce bias, particularly in patient selection and outcome assessment.
  • Small sample size limits generalizability of the findings to broader populations.
  • Lack of long-term follow-up data restricts understanding of the durability of treatment effects.
Conclusion:

SBRT demonstrates potential as a viable treatment option for adrenal and renal malignancies, warranting further investigation to confirm efficacy and safety.

Original Source(s)

Stereotactic Body Radiotherapy: is less fractionation more effective in adrenal and renal malignant lesions?

  • by Daniel Rivas, Alejandro de la Torre-Luque, Elena Moreno-Olmedo, Paloma Moreno, Vladimir Suárez, Ana Serradilla, Gregorio Arregui, David Álvarez, Morena Sallabanda, Antonio Lazo, María Isabel Núñez, Escarlata López

  • July 24, 2024

Related Content

Precision Oncology in Practice: How Theranostics Personalizes Treatment

In precision oncology, theranostics stands out as a transformative approach that tailors cancer treatment to the unique molecular profile of each patient. By integrating advanced diagnostic imaging with targeted therapy, theranostics ensures that treatments are customized to the unique characteristics of each patient's cancer, thereby optimizing efficacy and minimizing adverse effects.

  • by

  • May 11, 2025

  • 4 min
Long-term outcomes of active surveillance for clinically localized prostate cancer in a community-based setting: results from a prospective non-interventional study

Beyond Treatment Volume: When Pelvic Radiotherapy May Still Matter in High-Risk Localised Prostate Cancer